234 related articles for article (PubMed ID: 36073208)
1. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
2. MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
Jiao M; Zhang F; Teng W; Zhou C
Int J Gen Med; 2022; 15():3003-3030. PubMed ID: 35313552
[TBL] [Abstract][Full Text] [Related]
3. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
4. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
5. MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer.
Liang HB; Cao Y; Ma Q; Shu YJ; Wang Z; Zhang F; Ye YY; Li HF; Xiang SS; Song XL; Xu Y; Zhang YC; Bao RF; Yuan RY; Zhang YJ; Hu YP; Jiang L; Li ML; Wang XA; Wu XS; Wu WG; Zhao S; Fand Y; Cui XP; Lu YS; Zhou J; Zheng L; Gong W; Liu YB
Cell Physiol Biochem; 2017; 41(5):2117-2131. PubMed ID: 28427077
[TBL] [Abstract][Full Text] [Related]
6. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
8. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of MYBL2 predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.
Le L; Luo J; Wu H; Chen L; Tang X; Fu F
Eur J Histochem; 2021 Mar; 65(2):. PubMed ID: 33782625
[TBL] [Abstract][Full Text] [Related]
10. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.
Zhang X; Lv QL; Huang YT; Zhang LH; Zhou HH
J Exp Clin Cancer Res; 2017 Aug; 36(1):105. PubMed ID: 28784180
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
12. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells.
Li J; Chen H
Bioengineered; 2022 Apr; 13(4):9019-9031. PubMed ID: 35341461
[TBL] [Abstract][Full Text] [Related]
13. LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis.
Mu X; Shen Z; Lin Y; Xiao J; Xia K; Xu C; Chen B; Shi R; Zhu A; Sun X; Tao T; Song X; Xuan Q
Oxid Med Cell Longev; 2022; 2022():8693259. PubMed ID: 35557985
[TBL] [Abstract][Full Text] [Related]
14. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
15. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
16. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
19. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
[TBL] [Abstract][Full Text] [Related]
20. BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway.
Shi Z; Xiao C; Lin T; Wu J; Li K
Cell Cycle; 2021 May; 20(9):894-902. PubMed ID: 33886419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]